Sawai Launches Eight Generic Drugs with 23 Strengths

Upsher-Smith and Rafarm Announce Launch of Moxifloxacin Ophthalmic Solution, USP 0.5%

Message from the Chairman and Group CEO

Long-Term Vision for 2030 and Medium-Term Business Plan

Financial Summary for the Fiscal Year Ended March 31, 2021

FY2020 Financial Results

Sawai Group Holdings Announces Forecast of Business Results and Dividends for Fiscal 2021

Sawai Group Holdings Announces Posting of Impairment Loss and Revision of Forecast at Sawai Pharmaceutical